Sugammadex and rocuronium-induced anaphylaxis

Journal of Anesthesia

Volumn 30, Issue 2, 2016, Pages 290-297

  Takazawa, Tomonori ^a   Mitsuhata, Hiromasa ^b   Mertes, Paul Michel ^c  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^c HÔPITAL CIVIL   (France)

Author keywords

Anaphylaxis; Flow cytometry; Neuromuscular blocking agent; Rocuronium; Sugammadex

Indexed keywords

PHOLCODINE; ROCURONIUM; SUGAMMADEX; ANDROSTANE DERIVATIVE; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT; SUXAMETHONIUM; VECURONIUM;

ANAPHYLAXIS; ANESTHESIA; CLINICAL FEATURE; FLOW CYTOMETRY; HUMAN; INTRAOPERATIVE PERIOD; LABORATORY TEST; REVIEW; SKIN TEST; ADVERSE EFFECTS; CHEMICALLY INDUCED;

ANAPHYLAXIS; ANDROSTANOLS; ANESTHESIA; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SUCCINYLCHOLINE; VECURONIUM BROMIDE;

EID: 84949500669     PISSN: 09138668     EISSN: 14388359     Source Type: Journal    
DOI: 10.1007/s00540-015-2105-x     Document Type: Review

References (60)

1. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex. J Crit Care. 2009;24(1):29–35.
2. Sadleir PH, Clarke RC, Bunning DL, Platt PR. Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011. Br J Anaesth. 2013;110(6):981–7.
3. Reddy JI, Cooke PJ, van Schalkwyk JM, Hannam JA, Fitzharris P, Mitchell SJ. Anaphylaxis is more common with rocuronium and succinylcholine than with atracurium. Anesthesiology. 2015;122(1):39–45.
4. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A. Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–7.
5. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123(2):434–42.
6. Mertes PM, Malinovsky JM, Jouffroy L. Working Group of the S, Sfa, Aberer W. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21(6):442–53.
7. Dong SW, Mertes PM, Petitpain N, Hasdenteufel F, Malinovsky JM. Gerap. Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007). Minerva Anestesiol. 2012;78(8):868–78.
8. Laake JH, Rottingen JA. Rocuronium and anaphylaxis—a statistical challenge. Acta Anaesthesiol Scand. 2001;45(10):1196–203.
9. Guttormsen AB. Allergic reactions during anaesthesia—increased attention to the problem in Denmark and Norway. Acta Anaesthesiol Scand. 2001;45(10):1189–90.
10. Mertes PM, Volcheck GW. Anaphylaxis to neuromuscular-blocking drugs: all neuromuscular-blocking drugs are not the same. Anesthesiology. 2015;122(1):5–7.
11. Takazawa T, Tomita Y, Yoshida N, Tomioka A, Horiuchi T, Nagata C, Orihara M, Yamada MH, Saito S. Three suspected cases of sugammadex-induced anaphylactic shock. BMC Anesthesiol. 2014;14:92.
12. Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia. 2014;69(11):1251–7.
13. Baldo BA, McDonnell NJ. Sugammadex and anaphylaxis in the operating theater. Rev Esp Anestesiol Reanim. 2014;61(5):239–45.
14. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–6.
15. Mertes PM, Tajima K, Regnier-Kimmoun MA, Lambert M, Iohom G, Gueant-Rodriguez RM, Malinovsky JM. Perioperative anaphylaxis. Med Clin North Am. 2010;94(4):761–89.
16. Nel L, Eren E. Peri-operative anaphylaxis. Br J Clin Pharmacol. 2011;71(5):647–58.
17. Florvaag E, Johansson SG. The pholcodine story. Immunol Allergy Clin North Am. 2009;29(3):419–27.
18. Johansson SG, Oman H, Nopp A, Florvaag E. Pholcodine caused anaphylaxis in Sweden 30 years ago. Allergy. 2009;64(5):820–1.
19. Florvaag E, Johansson SG, Irgens A, de Pater GH. IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market. Allergy. 2011;66(7):955–60.
20. Johansson SG, Florvaag E, Oman H, Poulsen LK, Mertes PM, Harper NJ. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy. 2010;65(4):498–502.
21. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015;519(7542):237.
22. Munro IC, Newberne PM, Young VR, Bar A. Safety assessment of gamma-cyclodextrin. Regul Toxicol Pharmacol. 2004;39(Suppl 1):S3–13.
23. Mertes PM, Laxenaire MC, Alla F. Groupe d’Etudes des Reactions Anaphylactoides P. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003;99(3):536–45.
24. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115(3 Suppl 2):S483–523.
25. Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol. 2006;117(2):367–77.
26. Simons FE, Frew AJ, Ansotegui IJ, Bochner BS, Golden DB, Finkelman FD. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2–24.
27. Godai K, Hasegawa-Moriyama M, Kuniyoshi T, Kakoi T, Ikoma K, Isowaki S. Three cases of suspected sugammadex-induced hypersensitivity reactions. Br J Anaesth. 2012;109(2):216–8.
28. Galvao VR, Giavina-Bianchi P, Castells M. Perioperative anaphylaxis. Curr Allergy Asthma Rep. 2014;14(8):452.
29. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet. 1977;1(8009):466–9.
30. Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology. 2005;102(5):897–903.
31. Kroigaard M, Garvey LH, Gillberg L, Johansson SG, Mosbech H, Florvaag E. Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia. Acta Anaesthesiol Scand. 2007;51(6):655–70.
32. Laroche D, Gomis P, Gallimidi E, Malinovsky JM, Mertes PM. Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia. Anesthesiology. 2014;121(2):272–9.
33. Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H. Biochemical markers of anaphylactoid reactions to drugs. Comparison of plasma histamine and tryptase. Anesthesiology. 1991;75(6):945–9.
34. Simons FE. Anaphylaxis: Recent advances in assessment and treatment. J Allergy Clin Immunol. 2009;124(4):625-36; quiz 37-8.
35. Laroche D, Chollet-Martin S, Leturgie P, Malzac L, Vergnaud MC, Neukirch C. Evaluation of a new routine diagnostic test for immunoglobulin E sensitization to neuromuscular blocking agents. Anesthesiology. 2011;114(1):91–7.
36. Volcheck GW, Mertes PM. Local and general anesthetics immediate hypersensitivity reactions. Immunol Allergy Clin North Am. 2014;34(3):525–46.
37. Mertes PM, Lambert M, Gueant-Rodriguez RM, Aimone-Gastin I, Mouton-Faivre C, Moneret-Vautrin DA. Perioperative anaphylaxis. Immunol Allergy Clin North Am. 2009;29(3):429–51.
38. Mertes PM, Moneret-Vautrin DA, Leynadier F, Laxenaire MC. Skin reactions to intradermal neuromuscular blocking agent injections—a randomized multicenter trial in healthy volunteers. Anesthesiology. 2007;107(2):245–52.
39. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB. Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702–12.
40. Clarke RC, Sadleir PH, Platt PR. The role of sugammadex in the development and modification of an allergic response to rocuronium: evidence from a cutaneous model. Anaesthesia. 2012;67(3):266–73.
41. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol. 1991;88(3 Pt 1):328–38.
42. Takazawa T, Horiuchi T, Yoshida N, Yokohama A, Saito S. Flow cytometric investigation of sugammadex-induced anaphylaxis. Br J Anaesth. 2015;114(5):858–9.
43. Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy. 2006;61(8):935–9.
44. Song WJ, Chang YS. Recent applications of basophil activation tests in the diagnosis of drug hypersensitivity. Asia Pac Allergy. 2013;3(4):266–80.
45. Harper NJ, Dixon T, Dugue P, Edgar DM, Fay A, Gooi HC. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia. 2009;64(2):199–211.
46. Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2010;65(10):1205–11.
47. Dewachter P, Mouton-Faivre C, Emala CW. Anaphylaxis and anesthesia: controversies and new insights. Anesthesiology. 2009;111(5):1141–50.
48. McDonnell NJ, Pavy TJ, Green LK, Platt PR. Sugammadex in the management of rocuronium-induced anaphylaxis. Br J Anaesth. 2011;106(2):199–201.
49. Kawano T, Tamura T, Hamaguchi M, Yatabe T, Yamashita K, Yokoyama M. Successful management of rocuronium-induced anaphylactic reactions with sugammadex: a case report. J Clin Anesth. 2012;24(1):62–4.
50. Funnell AE, Griffiths J, Hodzovic I. A further case of rocuronium-induced anaphylaxis treated with sugammadex. Br J Anaesth. 2011;107(2):275–6.
51. Barthel F, Stojeba N, Lyons G, Biermann C, Diemunsch P. Sugammadex in rocuronium anaphylaxis: dose matters. Br J Anaesth. 2012;109(4):646–7.
52. Jones PM, Turkstra TP. Mitigation of rocuronium-induced anaphylaxis by sugammadex: the great unknown. Anaesthesia. 2010;65(1):89–90.
53. Baldo BA, McDonnell NJ, Pham NH. The cyclodextrin sugammadex and anaphylaxis to rocuronium: is rocuronium still potentially allergenic in the inclusion complex form? Mini Rev Med Chem. 2012;12(8):701–12.
54. Baldo BA, McDonnell NJ, Pham NH. Drug-specific cyclodextrins with emphasis on sugammadex, the neuromuscular blocker rocuronium and perioperative anaphylaxis: implications for drug allergy. Clin Exp Allergy. 2011;41(12):1663–78.
55. Leysen J, Bridts CH, De Clerck LS, Ebo DG. Rocuronium-induced anaphylaxis is probably not mitigated by sugammadex: evidence from an in vitro experiment. Anaesthesia. 2011;66(6):526–7.
56. Kawano T, Yokoyama M. Can sugammadex encapsulation eliminate the antigenic activity of aminosteroidal neuromuscular blocking agent? J Anesth. 2011;25(6):953–4.
57. Platt PR, Clarke RC, Johnson GH, Sadleir PH. Efficacy of sugammadex in rocuronium-induced or antibiotic-induced anaphylaxis. A case-control study. Anaesthesia. 2015;70(11):1264–7.
58. Rose M, Fisher M. Rocuronium: high risk for anaphylaxis? Br J Anaesth. 2001;86(5):678–82.
59. Fisher MM, Merefield D, Baldo B. Failure to prevent an anaphylactic reaction to a second neuromuscular blocking drug during anaesthesia. Br J Anaesth. 1999;82(5):770–3.
60. Thacker MA, Davis FM. Subsequent general anaesthesia in patients with a history of previous anaphylactoid/anaphylactic reaction to muscle relaxant. Anaesth Intensive Care. 1999;27(2):190–3.